NASDAQ:MNMD

Mind Medicine (MindMed) News Headlines

0.67

-0.01 (-1.91%)

(As of 06/29/2022 08:58 PM ET)

Add

Compare

Today's Range: 0.66
▼
0.69
50-Day Range: 0.66
▼
1.04
52-Week Range: 0.63
▼
3.67

Volume: 1.64 million shs
Average Volume: 3.83 million shs
Market Capitalization: $281.77 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: 8.50

Get Mind Medicine (MindMed) News Delivered to You Automatically

MNMD Media Mentions By Week

MNMD Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

MNMD
News Sentiment
▼
0.20

0.54
▲
Average
Medical
News Sentiment

MNMD News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

MNMD Articles
This Week
▼
6

1
▲
MNMD Articles
Average Week

MNMD Stock News Headlines Today

Source

Source	Headline
	Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) CEO Robert Barrow Sells 36,762 Shares americanbankingnews.com - June 29 at 5:28 AM
	Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) Insider Dan Karlin Sells 26,238 Shares of Stock americanbankingnews.com - June 29 at 5:28 AM
	Robert Barrow Sells 21,275 Shares of Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) Stock americanbankingnews.com - June 23 at 5:48 AM
	Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) Receives Consensus Recommendation of "Buy" from Analysts americanbankingnews.com - June 15 at 2:50 AM
	Mindmed Announces Voting Results for Annual General and Special Meeting finance.yahoo.com - June 1 at 5:35 PM
	IIROC Trading Halt - MMED.WT finance.yahoo.com - May 26 at 12:59 PM
	Mind Medicine Names Schond Greenway as Financial Chief >MNMD marketwatch.com - May 23 at 8:57 AM
	MindMed Names Schond Greenway As CFO nasdaq.com - May 23 at 8:57 AM
	MindMed Appoints Schond L. Greenway as Chief Financial Officer finance.yahoo.com - May 23 at 8:57 AM
	Mind Medicine: Focusing on Treatments, Not Revenue nasdaq.com - May 19 at 10:15 PM
	MindMed Reports First Quarter 2022 Financial Results and Business Highlights finance.yahoo.com - May 16 at 8:53 AM
	Why Earnings Season Could Be Great for Mind Medicine (MNMD) nasdaq.com - May 12 at 1:33 PM

	MindMed to Host Key Opinion Leader Webinar on Substance Use Disorders and Withdrawal Management finance.yahoo.com - May 12 at 7:46 AM
	MindMed Collaborators Prof. Liechti and Dr. Holze Announce Positive Topline Data from Phase 2 Trial Evaluating LSD in Anxiety Disorders finance.yahoo.com - May 11 at 11:45 AM
	MindMed to Host Earnings Call to Discuss First Quarter 2022 Financial Results and Provide Business Update finance.yahoo.com - May 9 at 9:38 AM
	Microsmallcap.com: Oregon to Become the First State to Legally Roll Out Psilocybin finanznachrichten.de - April 28 at 9:11 AM
	EXCLUSIVE: Why Kevin O'Leary Of 'Shark Tank' Says Public Psychedelics Companies Will Need To Merge markets.businessinsider.com - April 19 at 2:14 PM
	MindMed CEO: ‘We see a massive opportunity’ in the psychedelic medicine industry finance.yahoo.com - April 7 at 9:34 PM
	MindMed Appoints Francois Lilienthal As New CCO markets.businessinsider.com - April 5 at 7:17 PM
	MindMed Appoints Francois Lilienthal, MD as Chief Commercial Officer finance.yahoo.com - April 5 at 10:04 AM
	Novamind To Host MindMed Phase IIb Trial For LSD Based Drug For Anxiety Treatment benzinga.com - March 16 at 4:29 PM
	Novamind Inc.: Novamind to Host MindMed Phase IIb Trial for LSD and Anxiety finanznachrichten.de - March 16 at 11:28 AM
	MindMed to Participate in March Investor Conferences finance.yahoo.com - March 9 at 11:18 AM
	MindMed Announces Publication of Study Comparing the Acute Effects of Lysergic Acid Diethylamide and Psilocybin in Healthy Subjects finance.yahoo.com - March 2 at 8:08 AM
	MindMed Converts Shares To Have A Single Class benzinga.com - February 23 at 11:19 AM
	MindMed gets FDA OK to start trial for pharmacological LSD in anxiety disorder seekingalpha.com - January 25 at 12:20 PM
	Why MindMed Is Rising In Pre-market? nasdaq.com - January 25 at 12:20 PM
	Why Mind Medicine Shares Are Rising Today markets.businessinsider.com - January 25 at 12:20 PM
	MindMed begins enrollment in Session Monitoring System study for sensory data seekingalpha.com - January 18 at 3:33 PM
	MindMed Enrolls First Participant in a Study of its Session Monitoring System finance.yahoo.com - January 18 at 10:32 AM
	Stephen Hurst Resigns from MindMed Board of Directors finance.yahoo.com - January 7 at 7:25 PM
	MindMed Completes Phase 1 Clinical Trial Of Non-Hallucinogenic Proprietary Derivative Of Ibogaine markets.businessinsider.com - January 6 at 5:15 AM
	Do Options Traders Know Something About MindMed (MNMD) Stock We Don't? nasdaq.com - December 28 at 1:28 PM
	MindMed: FDA Issues Clinical Hold On Initial IND Submission Related To Phase 2b Trial Of LSD nasdaq.com - December 22 at 3:33 AM

	MindMed Names Robert Barrow New CEO; Vallone To Replace Dellelce As Chairman nasdaq.com - December 14 at 8:41 AM
	EXCLUSIVE: MindMed CEO Rob Barrow On Growth Aspirations, Development Pipeline msn.com - December 11 at 2:34 PM
	MindMed and Liechti Lab publish first human data on the interacting effects of an SSRI and psilocybin finance.yahoo.com - November 30 at 10:05 AM
	3 Psychedelics Stocks Wall Street Predicts Will Soar stocknews.com - November 24 at 11:13 AM
	MindMed Launches Study of Low-Dose LSD Effects on Sleep and Cognitive Measures finance.yahoo.com - November 16 at 8:55 AM
	MindMed Announces Financial Results for the Third Quarter 2021 and Business Highlights; Cash Balance of $145.9 USD ($185.4 CAD) to Execute on Diverse Clinical Pipeline finance.yahoo.com - November 15 at 9:18 AM
	MindMed Appoints Dr. Maria Oquendo to its Scientific Advisory Board finance.yahoo.com - November 5 at 8:49 AM
	MindMed Expands its Drug Development Pipeline with Launch of R(-)-MDMA Program finance.yahoo.com - October 26 at 10:24 AM
	MindMed Joins Clinical Trials Transformation Initiative finance.yahoo.com - October 21 at 10:42 AM
	OilPrice.com: Two Trillion-Dollar Industries Being Transformed By Tech finanznachrichten.de - October 20 at 8:43 AM
	MindMed Announces Appointment of Andreas Krebs and Carol Vallone as Directors and Transition of Bruce Linton finance.yahoo.com - September 30 at 8:05 AM
	MindMed to present at the Benzinga Healthcare Small Cap Conference finance.yahoo.com - September 28 at 9:09 AM
	Mind Medicine (MindMed) Inc. wsj.com - September 14 at 10:59 PM
	MindMed and BioXcel Therapeutics Publish an International Patent Application Describing a System for Identifying Agitation Episodes finance.yahoo.com - September 2 at 9:10 AM
	Mind Medicine: Short-Term Catalysts Fall Flat seekingalpha.com - August 24 at 6:10 PM
	MindMed Interim CEO on the growing competition in psychedelics industry finance.yahoo.com - July 29 at 3:03 PM

Get Mind Medicine (MindMed) News Delivered to You Automatically

This page (NASDAQ:MNMD) was last updated on 6/30/2022 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms